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Abstract
Background: The alkaline protease from Pseudomonas aeruginosa (AprA) is a member of the
metzincin superfamily of metalloendoproteases. A key feature of these proteases is a conserved
methionine-containing 1,4-tight β turn at the base of the active site zinc binding region.
Results: To explore the invariant methionine position in this class of protease, incorporation of a
nonnatural fluorinated methionine, L-difluoromethionine (DFM), into this site was accomplished.
Although overproduction of the N-terminal catalytic fragment of AprA resulted in protein
aggregates which could not be resolved, successful heterologous production of the entire AprA
was accomplished in the presence and absence of the nonnatural amino acid. DFM incorporation
was found to only slightly alter the enzyme kinetics of AprA. In addition, differential scanning
calorimetry indicated no significant alteration in the thermal stability of the modified enzyme.
Conclusion: Although invariant in all metzincin proteases, the methionine 214 position in AprA
can be successfully replaced by the nonnatural amino acid DFM resulting in little effect on protein
structure and function. This study indicates that the increased size of the methyl group by the
introduction of two fluorines is still sufficiently non-sterically demanding, and bodes well for the
application of DFM to biophysical studies of protein structure and function in this class of protease.
Background
The metzincin superfamily of proteases includes the
matrixins, astacins, reprolysins, snapalysins, leish-
manolysins and serralysins [1,2]. These zinc-dependent
endoproteases may act on a large number of substrates, or
they may be highly specific, targeting only one or a few
proteins or oligopeptides. There are over 700 different
enzymes that have been classified as metzincins and they
are produced by organisms ranging from bacteria to
plants and animals [3]. As diverse as the members of this
superfamily are, surprisingly they all share a structurally
similar catalytic site which includes a common zinc bind-
ing motif and an absolutely conserved methionine-con-
taining 1,4-tight β turn, termed the "Met-turn" in their
active sites [4].
Many of the metzincin proteases are of medical signifi-
cance. The matrixins, or matrix metalloproteinases
(MMPs) include the collagenases, gelatinases and strome-
lysins [5,6]. Members of this subfamily not only degrade
extracellular matrix for tissue remodeling and maturation,
but they have also been found to release and activate sev-
eral growth factors and modulate chemotactic signals [5].
In disease processes, however, they have been implicated
in promoting tumour invasion and metastasis by degrada-
tion of matrix barriers, exacerbating periodontal disease,
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and destroying aggrecan and collagen in rheumatoid
arthritis. For this reason, much interest has arisen in
mechanistic and inhibitor studies of MMPs [7-9]. The
astacins comprise a subfamily of enzymes involved in
digestion, developmental regulation, and peptide process-
ing. The reprolysins or adamalysins are mainly responsi-
ble for the hemorrhagic effects and tissue necrosis typical
of snake bites [2]. These effects are caused mainly by
destruction of the extra-cellular matrix surrounding capil-
laries in conjunction with the inhibition of platelet aggre-
gation by disintegrins. The N-terminal catalytic domains
of members of this family are usually zinc and calcium
dependent, while the C-terminal portion may be disin-
tegrin, cysteine-rich, or lectin type domains with hemor-
rhagic or cell adhesion properties. Mammalian
adamalysins play important roles in reproduction, myo-
genesis and cytodifferentiation as well as in disorders such
as asthma, cardiac hypertrophy, and endotoxic shock [10-
13]. The snapalysins are secreted proteases from several
Streptomyces organisms and the membrane-bound leish-
manolysins originate from a number of protozoan para-
sites. The serralysins, of which the alkaline protease from
P. aeruginosa (AprA) is a member, are secreted by several
pathogenic, gram-negative bacterial species [14]. They are,
on average, 50 kDa proteins consisting of 2 domains; the
C-terminal domain binds up to eight calcium ions in a
mainly structural role, but also contains the secretion sig-
nal. The catalytic site is located in a cleft on the N-terminal
domain (Figure 1)[15]. The physiologic substrate(s) of
these enzymes are not known with certainty, but are
thought to be proteins of the extracellular matrix and pos-
sibly immune response elements such as interferon
gamma and complement proteins [16,17].
To add a further dimension to the techniques applied to
the analysis of protein structure and function, the incor-
poration of nonnatural amino acids into proteins is cur-
rently of great interest. One aspect of this approach is the
incorporation of amino acids containing fluorine which
would be applicable to not only probing subtle steric
interactions in proteins (Van der Waals' radius of F is 1.47
Å vs. 1.20 Å for H), but also in applying 19F spectroscopy
to this area [18,19]. In order to probe the methionine
position in this class of proteins (specifically AprA), the
fluorinated analogue, S-difluoromethyl-L-homocysteine
(L-difluoromethionine, (DFM)), was utilized to replace
the methionine in the Met-turn and to determine its
effects on catalytic activity and thermal stability.
Results
N-terminal catalytic fragment
Attempts to overproduce the N-terminal catalytic frag-
ment of AprA which consisted of residues T40 to N258 of
the 479 residue protein led to the production of aggre-
gates in spite of attempts to increase soluble protein
expression by control of temperature, isopropyl-β-D-thi-
ogalactopyranoside (IPTG) concentration, co-expression
of folding chaperones (GroES and GroEL) as well as secre-
tion and fusion to a NusA solubility tag [20-23]. In several
attempts at resolubilisation of these inclusion bodies (see
Methods for details), semi-soluble aggregates of the trun-
cated AprA were detected by gel filtration chromatography
(Superose-12) having molecular weights higher than the
exclusion limit of the resin (>2 × 106 Da). Due to the dif-
ficulty of isolating and handling sufficient quantities of
this truncated version of AprA, attention was then focused
on overproduction of the full-length mature form of AprA
which corresponds to residues G10 to V479.
Mature full-length AprA and DFM incorporation
The gene for the full-length mature form of AprA [24-26]
which corresponds to residues G10 to V479 was isolated
on to pET22b and overexpressed in E. coli BL21 (λDE3),
resulting in inclusion body formation. Isolation of the
protein aggregates followed by solubilisation and refold-
ing produced an active, stable and soluble enzyme of 49
500 Da, according to mass spectrometric analysis (Figure
2 and 3). L-DFM was synthesized as previously described
[27,28] and incorporated into AprA using the methionine
auxotrophic  E. coli strain, B834 (λDE3). The resulting
inclusion bodies were refolded in an identical manner as
Ribbon representation of alkaline protease from P. aeruginosa  (AprA) Figure 1
Ribbon representation of alkaline protease from P. aeruginosa 
(AprA). The active site zinc ion is shown in blue and the con-
served methionine in yellow spacefill just below the zinc. Cal-
cium ions in the C-terminal β-roll domain are green. Figure 
generated using WebLab Viewer Pro 3.7 using PDB entry 
1KAP [15].BMC Biochemistry 2005, 6:21 http://www.biomedcentral.com/1471-2091/6/21
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the non-labelled protein, and the expected 49 535 Da pro-
tein, as determined by electrospray mass spectrometry
(ESMS), was isolated (Figure 2 and 4).
Kinetic analysis and differential scanning calorimetry
Utilizing a previously reported spectrophotometric
method for kinetic analysis of AprA, the mature, full-
length recombinant protein showed similar kinetic prop-
erties for hydrolysis of Z-Arg-Arg-p-nitroanalide to those
reported for the mature wild-type protein, isolated
directly from P. aeruginosa growth media [29]. The kcat val-
ues were determined to be 1.6 ± 0.1 min-1 versus 0.6 ± 0.1
min-1 and the Km values were 12.6 ± 2.4 µM vs. 6 ± 1 µM
for the enzyme produced by the cognate organism and the
recombinant protein respectively.
Slightly improved assay conditions were found by increas-
ing the amount of enzyme from 25 µg per assay to 100 µg
in order to improve sensitivity, and by replacing the assay
buffer from 5 mM TRIS to 20 mM HEPES to avoid possi-
ble metal binding effects of the TRIS buffer. The kinetic
parameters of non-labelled and DFM-labelled AprA pro-
teins were compared under the new conditions and found
to be similar. The Km was not significantly altered (15.4 ±
0.9 µM for the unlabelled protein vs. 14 ± 2 µM for the
DFM-incorporated), and the kcat was only slightly affected
by DFM incorporation, showing a decrease from 0.57 ±
0.02 min-1 to 0.44 ± 0.02 min-1.
Due to the proximity of the Met214 residue to the metal
ligands which ligate the zinc ion (Figure 5), the effect of
substitution of this Met with the larger DFM residue on
thermal denaturation was investigated. Replicate differen-
tial scanning calorimetry experiments were performed on
both the mature full-length AprA and the DFM-labelled
mature full-length AprA (DFM-AprA) in 20 mM HEPES
(pH 7.8). The Tmax for unlabelled and DFM-labelled AprA
were determined to be 58.7 ± 0.1°C and 58.6 ± 0.2°C
respectively (Figure 6).
19F NMR spectroscopy
DFM-labelled mature full-length AprA was analyzed by
19F nuclear magnetic resonance (19F NMR) spectroscopy
without proton decoupling to produce a complex set of
19F resonance multiplets centered at approximately -93.8
ppm. Paramagnetic line broadening with addition of
gadolinium(III)-N,N,N',N' -ethylenediaminetetraacetic
acid ((GdEDTA)-) complex resulted in line broadening of
all  19F resonances. Proton-decoupled 19F NMR experi-
ments resulted in collapse of the 19F multiplets, however
complete resolution of the N-terminal DFM from the
internal (DFM214) 19F resonances was still incomplete at
this field strength (564.5 MHz) (Figure 7).
Discussion
AprA is a member of the metzincin superfamily of metal-
loproteases and is one of several proteases secreted from
Pseudomonas aeruginosa into tissue of infected patients
[16,30,31] (Figure 1). It appears that a combination of
AprA, elastase (LasB) and LasA protease and protease IV
work in concert to produce tissue invasion [32,33]. AprA
is biosynthesized in P. aeruginosa as a 479 residue
polypeptide which is secreted via a C-terminal signal
sequence directly into the extra cellular medium where a
9 amino acid N-terminal inhibitory propeptide is autocat-
alytically removed [26]. A critical aspect to the structure-
function of AprA and the metzincins in general is the
active-site arrangement of the metal ligands and the still
incompletely understood methionine-containing 1,4-
tight β turn at the base of the active site present in all
members of the metzincin superfamily. Although much is
known concerning the cellular biochemistry of a number
of metzincins, detailed knowledge of the function of the
components of the active site is still lacking. For example,
methionine residues in proteins are less frequent in occur-
rence than many other residues (third least abundant after
tryptophan and cysteine [34]) and it can frequently be
replaced with other hydrophobic amino acids such as leu-
cine [35,36]. However the surprising persistent presence
of methionine in over 700 members of this class of pro-
tease has been noted[3,4,37,38]. Attempts to define the
contribution that this seemingly quintessential amino
acid plays in this class of enzyme have indicated that,
depending upon the specific superfamily member stud-
ied, some flexibility in replacement may be possible, at
least in vitro. For example, in the case of MMP-2 (gelati-
SDS-PAGE gel summary of the refolding of mature full-length  AprA Figure 2
SDS-PAGE gel summary of the refolding of mature full-length 
AprA. S represents the supernatant of the crude lysate, W1 
is the solution from the first wash of the inclusion body pel-
let, RF is the refolded protein and HS is the refolded protein 
after the high salt wash and DA is the refolded DFM-AprA.BMC Biochemistry 2005, 6:21 http://www.biomedcentral.com/1471-2091/6/21
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nase A), enzymes with replacements of the active site Met
with either Leu or Ser have only minor perturbations in
catalytic activity [39]. In the case of protease C from
Erwinia chrysanthemi, replacement of the active site
methionine (Met226) by leucine, alanine or isoleucine
resulted in enzyme mutants sufficiently stable to be iso-
lated, but this was not so with M226H, M226S or M226N
mutations. However the enzyme kinetic properties of the
M226L, M226A and M226I mutants were compromised
and crystallographic studies indicated some alteration of
the zinc binding histidines which might explain the
effects of these mutations on the kinetic properties of the
enzyme [40].
Substitution of the active site Met by selenomethionine
(SeMet) in MMP-8 (human neutrophil collagenase) was
also found to be somewhat perturbing. In the catalytic
domain of MMP-8, SeMet appeared to decrease the pro-
tein's resistance to urea denaturation [41]. This loss of sta-
bility was accompanied by a considerable decrease in
activity and an increase in Km towards the substrate (7-
methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3- [2,4-
dinitrophenyl]-L- 2,3-diaminopropionyl)-Ala-Arg-NH2.
In a previous study using the substrate (dinitrophenyl-
Pro-Leu-Gly-Leu-Trp-Ala-D-Arg-NH2), however, kcat and
Km values were unaffected by SeMet replacement in MMP-
8 [42,43].
Evidently additional investigations into the properties of
the metzincins through modification of the methionine
position may be of importance. However the usual
ensemble of potential replacements of amino acid resi-
dues through site-directed mutagenesis is limited in gen-
eral to replacement with the other nineteen amino acids.
In order to explore the effects of alterations of the critical
methionine in the metzincin class of proteases, the intro-
duction of a sterically and electronically subtle methio-
nine analogue DFM, was the focus of the present study.
For these studies the alkaline protease from Pseudomonas
aeruginosa was initially investigated as it is representative
of the metzincin family of proteases, is important in tissue
invasion by this pathogen and has only two methionines
in its structure, the N-terminal methionine and the Met-
turn methionine, M214. The presence of only two
methionine residues in this metzincin (and only the
active site methionine if a mature secreted AprA is pro-
duced) facilitates bioincorporation of DFM into the pro-
tein without the use of complex cell free in-vitro
Positive ion mode electrospray mass spectrum of the refolded, full-length, mature AprA Figure 3
Positive ion mode electrospray mass spectrum of the refolded, full-length, mature AprA. The major peak in the spectrum (49 
500 Da) corresponds exactly to the recombinant protein without the initiator methionine. The peak at 49 534 Da may repre-
sent a calcium adduct. The peak at 49 632 Da corresponds to AprA retaining the N-terminal methionine.BMC Biochemistry 2005, 6:21 http://www.biomedcentral.com/1471-2091/6/21
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translation system approaches [44-46]. As well, this
choice of target protein for a preliminary study avoids
complications with additional bioincorporation of the
analogue into other methionine positions which may be
present in other members of the metzincin superfamily.
DFM is a subtle derivative of methionine that has been
shown to be useful as a 19F-NMR probe in proteins
[28,47]. Unlike leucine and isoleucine, this unbranched
analogue may only produce a moderate increase in the
steric properties of the methyl group due to the incorpo-
ration of two fluorine atoms. In addition, fluorination
could profoundly affect the electron density of the sulfur
atom [27]. As can be seen in Figure 5, the thiomethyl
group of M214 is in close proximity to H176, H180, and
H186 and may contribute to the proper positioning of
these metal ligands. Hence it was of interest to explore the
effects of this nonnatural amino acid on the catalytic activ-
ity and thermal stability of the modified protein by intro-
duction of L-difluoromethionine into the critical
methionine position in the Met-turn.
Previous studies on other metzincins such as stromelysin,
MMP-8, and astacin have shown that the truncated
enzymes containing only the catalytic domain of these
enzymes could be expressed and were sufficiently stable to
be studied [48-50]. In the current study, initial attempts
were therefore focused on the overproduction of the
smaller N-terminal catalytic domain of AprA (T40 to
N258). Although evidence for cellular production of this
fragment was observed, almost complete aggregation of
this fragment occurred under a variety of experimental
conditions designed for its control (Results). Previous
reports by Guzzo and co-workers have shown that even
minimal recombinant expression (1 µg/mL) of soluble,
intact AprA protein required the co-expression of the
entire secretion apparatus (AprD, AprE, AprF) [51]. When
the structural gene for AprA was expressed alone, how-
ever, intracellular accumulation of AprA was barely detect-
able, most likely due to rapid degradation inside the cell
[52]. In other reports, significant quantities of the enzyme
could be found intracellularly, but only in the form of
inclusion bodies, which are known to be highly resistant
to degradation [24,53,54].
Positive ion mode electrospray mass spectrum of DFM-AprA Figure 4
Positive ion mode electrospray mass spectrum of DFM-AprA. The calculated molecular weight of the labelled protein with the 
initiating residue was 49 702 Da, and without, 49 535 Da. Possible sodium adducts (2Na+) are seen for both species at 49 747 
Da and 49 581 Da.BMC Biochemistry 2005, 6:21 http://www.biomedcentral.com/1471-2091/6/21
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However successful production of mature full length
(G10 to V479) AprA, was accomplished without the co-
expression of the entire secretion apparatus. Although
insoluble protein aggregates were produced, it was possi-
ble to resolubilise and refold the overexpressed protein,
yielding approximately 40 mg of high purity enzyme per
1 L of culture (Figure 2). The ESMS analysis revealed that
although the majority of the protein isolated from this
protocol had Mr = 49 500 Da (full length mature AprA,
G10-V479), a small quantity of inseparable enzyme with
an Mr = 49 632 Da had maintained its N-terminal methio-
nine (Met-G10-V479) from the cloning procedure (Figure
3). Kinetic analysis of this recombinant mature AprA com-
pared favourably with values previously reported [29] for
the wild type AprA secreted by P. aeruginosa (kcat/Km of
2140 ± 540 M-1s-1 and 1800 ± 300 M-1s-1 for wild type and
recombinant enzymes respectively).
An almost 100% incorporation level of the fluorinated
probe into AprA was readily accomplished by induction
of protein expression in minimal media supplemented
with 2 mM DFM. The labelled protein was also expressed
as intracellular inclusion bodies which were resolubilised
and refolded using the same protocol as the unlabelled
recombinant protein, yielding approximately 16 mg of
nearly homogeneous protein per 1 L of culture (Figure 2).
The ESMS analysis indicated that, unlike the unlabelled
recombinant AprA, a majority of the DFM incorporated
protein maintained the initiating residue (Mr = 49 702
Da), while this DFM was cleaved in only about one quar-
ter of the sample (Mr = 49 535 Da) (Figure 4). The inter-
esting observation that removal of the N-terminal DFM
residue occurs to a lesser extent compared to methionine
in this position indicates that the processing of fluori-
nated methionines by methionine aminopeptidase is a
less efficient process. Related to this observation is a recent
report by Budisa and coworkers indicating the lack of
removal of trifluoromethionine from the N-terminus of a
mutant green fluorescent protein[55]. It may be that the
increased steric size of the fluorinated methyl groups in
these analogues alters the correct positioning of the pep-
tide bond of the substrate in the active site of the methio-
nine aminopeptidase which could reduce hydrolytic
efficiency by this enzyme. In any event, the presence of the
N-terminal methionine (or DFM) is not expected to affect
catalytic activity or thermal stability of the protein as the
N-terminus is physically remote from the active site. The
kinetic characteristics of the protein mixture with and
without incorporated DFM were determined under the
revised conditions described in the methods and results
sections. The Km was not significantly altered by replace-
ment with DFM, the Vmax and therefore kcat were only
slightly impaired, resulting in a decrease in kcat/Km from
620 ± 30 M-1s-1 to 530 ± 50 M-1s-1.
Active site of AprA showing the environment of the conserved methionine (M214) Figure 5
Active site of AprA showing the environment of the conserved methionine (M214). A: The three histidine ligands (labelled) are 
shown along with the zinc ion (in green). The spacefill representation (B) shows the closely packed arrangement around the 
methionine residue, as well as its proximity to the catalytic zinc and the three histidine residues. Protons (white) were added 
to the M214 methyl group for clarity. Based on structure from PDB entry 1KAP [15].BMC Biochemistry 2005, 6:21 http://www.biomedcentral.com/1471-2091/6/21
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In order to compare the effects of DFM on thermal stabil-
ity of the protein, preliminary differential scanning calor-
imetry studies were undertaken on AprA and DFM-AprA.
Under the conditions utilized in these experiments, the
thermal denaturations of AprA and DFM-AprA were
found to be irreversible. As shown in Figure 6, the thermal
stability in 20 mM HEPES (pH 7.8) was not significantly
altered upon fluorination of the Met-turn methionine.
The Tmax  for unlabelled and DFM-labelled AprA were
determined to be 58.7 ± 0.1°C and 58.6 ± 0.2°C respec-
tively. This would indicate that the introduction of two
fluorine atoms into the methyl group, which is in close
contact to the critical histidines in the active site, can be
accommodated by the protein such that the catalytic
properties and thermal stability of AprA are not drastically
perturbed.
Due to the lack of background 19F resonances in most bio-
logical systems, the 100% natural abundance of the 19F
isotope and its sensitivity to NMR detection of 83 % to
that of 1H, the application of 19F spectroscopy to studies
in protein structure and function has been an important
biophysical technique that has been shown to give critical
information on the environment surrounding the fluo-
rine nucleus [19,56-58]. Previous studies on DFM incor-
poration into the transglycosylase of bacteriophage λ and
the leucine-isoleucine-valine (LIV) binding protein from
E. coli, have detected separate sets of resonances for each
DFM residue present in each protein and their presence
has been useful in detection of ligand binding [28,47]. As
the two fluorine atoms in DFM are diastereotopic due to
the presence of the chiral centre of the α-carbon of
methionine, complex 19F resonances can result. In fact, it
has been shown that a complex octet of 19F resonances is
observed when a DFM residue is located in a conforma-
tionally restricted protein environment [28]. It was there-
fore of interest to investigate the 19F NMR spectroscopy of
DFM-AprA. The 1H-coupled 19F NMR spectrum of DFM-
AprA (Figure 7A) is a composite of the 19F resonances not
only from the active site DFM at position 214, but also a
contribution from the presence of protein molecules still
maintaining the N-terminal DFM residue. Interestingly
the two resonances overlap in the 564 MHz spectrum. It
has previously been shown that application of paramag-
netic line broadening agents, such as Gd(EDTA)-  will
broaden the 19F NMR resonances from fluorine nuclei in
a protein in a distance-dependent manner and can serve
to indicate which 19F resonances originate from more
solution exposed residues [56,58]. To possibly distinguish
the signal contributions from each DFM, paramagnetic
line broadening experiments utilizing Gd(EDTA)- were
undertaken. These experiments (Figure 7B) indicated that
both DFM residues (DFM1 and DFM214) were equally
susceptible to the line-broadening agent, indicating that
close approach to the active site DFM by Gd(EDTA)- was
also possible in solution. Based on the crystal structure of
AprA [15,59], the active site is open to solvent and could
be expected to reasonably accommodate the rather large
Gd(EDTA)-  molecule resulting in little discrimination
between the two DFM residues. Although proton decou-
pling simplified the 19F spectrum (Figure 7C), the reso-
nances from the two DFM residues were still unresolved;
the complexity of which may also result from contribu-
tions of the restricted environment of the active site DFM.
Attempts to remove the N-terminal DFM with recom-
binant E. coli methionine aminopeptidase [60] under a
variety of conditions resulted in complex mixtures due to
proteolytic degradation by AprA. Additional attempts to
produce a variant of AprA lacking the N-terminal DFM
residue by introduction of the wild-type N-terminal self-
cleaving propeptide sequence or a thrombin cleavage site
resulted in extremely poor isolated yields of these forms of
the protease. Further studies will be focused on the appli-
cation of this NMR probe to investigating conformational
changes in the active site upon ligand and inhibitor bind-
ing.
Conclusion
The 19F biophysical probe, DFM, was successfully incor-
porated into the critical Met-turn of AprA and resulted in
minimal catalytic or structural alteration of the enzyme.
These findings are encouraging for the further application
of DFM as a subtle probe for the investigation of the metz-
incin family of proteases.
Differential scanning calorimetry data of both the unlabelled  AprA and the DFM-incorporated AprA Figure 6
Differential scanning calorimetry data of both the unlabelled 
AprA and the DFM-incorporated AprA. All scans were per-
formed at 1°C per minute in 20 mM HEPES (pH 7.8) and 
buffer scans were subtracted from sample runs.BMC Biochemistry 2005, 6:21 http://www.biomedcentral.com/1471-2091/6/21
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Methods
Materials
Restriction endonucleases were purchased from New Eng-
land BioLabs (Pickering, ON). The Expand™ and Pwo
polymerase kits as well as the alkaline phosphatase (from
calf intestine) were Roche (Laval, QC) products and the
Taq polymerase was from Qiagen (Mississauga, ON). The
thrombin (from bovine serum) was purchased from
Amersham Biosciences (Baie d'Urfé, QC). The peptide
substrate, Z-Arg-Arg-pNA, was purchased from Bachem
(King of Prussia, PA). The VP-DSC differential scanning
microcalorimeter and Origin™ software (Version 5.0)
were from MicroCal™ (Northampton, MA). 19F NMR data
were collected on Bruker Avance (Milton, ON) NMR spec-
trometers (500 and 600 MHz). Unless otherwise noted,
all reagents and chemicals were of the highest commercial
grade available and were used without further purifica-
tion. L-Difluoromethionine was prepared by a previously
reported method [28].
Cloning and bacterial expression
The genes of interest were amplified by PCR and digested
using the primers and restriction endonucleases listed in
Table 1. With the exception of pNusAPA, all PCR products
were ligated in to appropriately digested pET22b(+)
(Novagen Inc). The NusA fusion protein was produced
from a pET43.1b(+) based vector (Novagen Inc). New
constructs were confirmed by DNA sequencing (Mobix,
Inc) in both directions and the protein products were ana-
lyzed by electrospray mass spectrometry (positive ionisa-
tion mode).
Unlabelled proteins were produced in the E. coli strain
BL21 (λDE3), while strain B834 was used for DFM incor-
poration. A 10 mL starter culture (LB broth with 50 mg/
mL carbenicillin) was inoculated from frozen stock and
incubated overnight at 37°C with shaking. For the pro-
duction of unlabelled proteins, the entire starter was used
to inoculate 1 L of LB broth (with 50 mg/mL ampicillin)
and the culture was grown to an OD600 of 0.6 to 0.8. IPTG
was added directly to a final concentration of 1 mM and
the culture was incubated at 37°C with shaking for an
additional 4 hours. A similar procedure to that described
by Vaughan et al. [28] for DFM incorporation into phage
lysozyme was used to produce the L-DFM labelled AprA
protein. In brief, a 10 mL starter culture of E. coli strain
B834 harbouring plasmid pWApr was used to inoculate 1
L of M9 buffer (pH 7.2: 47.6 mM Na2HPO4, 22 mM
KH2PO4, 8.5 mM NaCl, 18.7 mM NH4Cl, 2 mM MgSO4,
0.1 mM CaCl2) supplemented with 0.4 % glucose, 50 µg/
mL ampicillin, and 0.1 mM L-Met. The culture was grown
at 37°C with shaking to an OD600 of approximately 0.7
and then harvested by centrifugation for 10 minutes at
5000 g. The cells were washed in M9 buffer and then
resuspended in M9 supplemented with 0.4 % glucose and
50 µg/mL ampicillin. After incubating at 37°C with shak-
ing for 30 minutes, 2 mM L-DFM and 1 mM IPTG were
added, and the culture was incubated (37°C with shak-
ing) for a further 8 hours.
Refolding of the N-terminal catalytic domain
The expressed N-terminal catalytic domain segment that
was initially produced was extracted and solubilised in
much the same manner as the full-length protein
described below. However, several variations to the
refolding buffer were made in attempts to recover the sol-
uble, active catalytic fragment. A range of pH conditions
from 7.2 to 8.0 was used. ZnSO4 was added to the refold-
ing buffer with concentrations ranging from 0.1 µM to 0.1
mM. Glycerol (20 %) was also added to the refolding
buffer and the L-arginine content was varied from 0.8 M
down to 0.2 M. The arginine was replaced completely in
several other attempts which instead involved 1 % Brij-35,
1 M non-detergent sulfobetaine 201 (NDSB-201), or 1 M
KCl with 20 % glycerol. Finally, the dialysis buffer was
19F NMR spectra of DFM-labelled AprA Figure 7
19F NMR spectra of DFM-labelled AprA. The 564.7 MHz 19F 
NMR spectrum of DFM-labelled AprA in D2O with approxi-
mately 40 mM HEPES (A) and with the addition of 2 mM 
Gd(EDTA)- (B). Proton-decoupled spectrum of DFM-labelled 
AprA (C).BMC Biochemistry 2005, 6:21 http://www.biomedcentral.com/1471-2091/6/21
Page 9 of 11
(page number not for citation purposes)
also varied to include 10–20 % glycerol, 0.05 % Brij-35 or
0.05 % Triton-X 100.
Solubilisation and refolding of the full-length AprA protein
Induced E. coli BL21 (λDE3) cells harbouring plasmid
pWApr were harvested in a 10 min spin at 5000 g, washed
in M9 buffer (47.6 mM Na2HPO4, 22 mM KH2PO4, 8.5
mM NaCl, 18.7 mM NH4Cl, 2 mM MgSO4, 0.1 mM
CaCl2) then resuspended in lysis buffer (50 mM TRIS (pH
7.8), 1 mM EDTA, 0.1 % Triton-X-100) and disrupted by
eight 20 second rounds of continuous sonication with
cooling. The crude cell lysate was centrifuged for 10 min-
utes at 6000 g, and the pellet was washed twice in lysis
buffer and then 3 times in lysis buffer without Triton.
The resulting inclusion body pellet was dissolved in a
small amount of solubilisation buffer (50 mM TRIS, pH
7.8, 1 mM EDTA, 6 M guanidine hydrochloride) and incu-
bated at 37°C for 1 hour. The solution was then centri-
fuged for 10 minutes at 13000 g and a 4 µL aliquot was
diluted to up to 1 mL in solubilisation buffer for an
absorbance measurement at 280 nm. Protein concentra-
tion was estimated using a predicted extinction coefficient
of 67 990 M-1cm-1 calculated by the ProtParam tool in
ExPASy [61]. Additional solubilisation buffer was used to
dilute the protein solution to 10 mg/mL. This solution
was then passed through a 0.22 µm syringe filter and
added dropwise with stirring to ice cold refolding buffer
(50 mM TRIS, pH 7.8, 1 mM CaCl2, 0.8 M L-arginine),
resulting in a 100-fold dilution (final refolding protein
concentration: 0.1 mg/mL). After an overnight incubation
with stirring at 4°C, the protein was dialysed against two
changes of buffer with metals (20 mM HEPES, pH 7.8, 1
mM CaCl2, 0.1 mM ZnSO4), then one without CaCl2 or
ZnSO4, but with 300 mM NaCl. Finally, the protein was
concentrated using an Amicon pressure filtration device
with a 10 kDa cut-off filter and the high salt buffer
exchanged to 20 mM HEPES (pH 7.8).
Mass spectrometry
Electrospray mass spectrometry of purified protein sam-
ples was carried out on a Micromass Q-TOF Global
Ultima mass spectrometer in positive ion mode. Spectra
were analyzed using the MaxEnt1 algorithm in the MassL-
ynx (V4.0, Micromass Limited/Waters, Milford, Massa-
chusetts) software. Buffer salts were removed from protein
samples using a Nanosep microcentrifuge concentrator
with a 10 kDa cut-off. Once in Milli-Q (Waters Corp.)
purified water, samples were diluted with a solution of 50
% acetonitrile and 0.1 % formic acid.
Activity assay
Initial determinations of kinetic parameters using the sub-
strate Z-Arg-Arg-p-nitro-analide were carried out under
the conditions described by Louis et al. for wild type alka-
line protease [29], using substrate concentrations ranging
from 3 µM to 200 µM. The rate of p-nitroanaline released
was calculated using the extinction coefficient of 8800 M-
1cm-1 at 410 nm [29]. In order to avoid possible metal
chelating effects of the TRIS buffer and to increase assay
sensitivity, 20 mM HEPES buffer was used in place of the
5 mM TRIS, and 100 µg of protein was used for each assay.
Kinetic parameters, Km and Vmax, were determined by non-
linear regression using the GraFit5™ software (Erithacus
Software Limited).
Differential scanning calorimetry
A protein concentration of 0.5 mg/mL was used for each
melting temperature determination. Initially, 50 mM TRIS
(pH 7.8) was used as the buffer for these experiments,
however, this was eventually replaced by 20 mM HEPES.
Therefore, protein samples in 20 mM HEPES (pH 7.8) and
Table 1: Primers and endonucleases used in the cloning of the various constructs. Restriction endonuclease cut sites are underlined 
and the regions of the primers homologous to the gene of interest are in bold.
Construct Primers Restriction 
endonucleases
Protein product
pAPA' N-terminal: 5' CCA GAA TTC CAT ATG  ACC GTC GAC CAG 
GCG GCG GAG C 3'
C-terminal: 5' CCA GGA TCC TTA GTT GGC CCC GTA GAG 
CTT CTG G 3'
NdeI
BamHI
AprA catalytic fragment 
(APA')
pPelAPA' N-terminal: 5' CCG AAT TCC ATG G CC GTC GCC GTC GAC 
CAG GCG GCG GAG C 3'
C-terminal: Same as pAPA'
NcoI APA' with pelB secretion 
signal
pNusAPA' N-terminal: 5' G GGC GGG GAC GAA TTG GTC AAT GGC 3'
C-terminal: Same as pAPA'
Blunt end ligation at N-
terminus: no digestion 
required
APA' with NusA solubility 
tag and His6 tag
pWApr N-termnal: 5' CCA GAA TTC CAT ATG GGT CGT AGC GAT GCG 
TAT ACC 3'
C-terminal: 5' CCA GGA TCC TCA GAC GAC GAT GTC GGC 
CTG G 3'
NdeI
BamHI
Mature AprA without 
pro-peptideBMC Biochemistry 2005, 6:21 http://www.biomedcentral.com/1471-2091/6/21
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reference buffer (20 mM HEPES, pH 7.8) were degassed
under vacuum just prior to analysis. Scanning was per-
formed continuously between 15 and 90°C at a rate of
1°C per minute with a 1 minute hold in between each up
and down scan. An initial buffer-buffer scan was per-
formed in order to establish a thermal history for the sys-
tem. The subsequent buffer-buffer scan was then used as a
reference. Once the temperature was below 35°C again,
the protein solution was loaded into the sample cell and
scanned several times.
Data were analysed using the Origin5.0(™) software in the
following manner. The reference buffer-buffer scan was
subtracted from the subsequent protein scan, the data
were normalised for protein concentration, and the tem-
perature (Tmax) at the resulting peak was determined. Plots
of heat capacity, Cp, versus temperature were then plotted.
(Tmax may be defined as the apparent temperature of max-
imum excess specific heat absorption [62,63]. The Tmax
values for both the mature wild type AprA and the DFM-
incorporated proteins were determined in triplicate, aver-
aged and the standard deviation determined.
19F NMR spectroscopy of DFM-labelled AprA
Protein was first dialysed against 5 mM HEPES (pH 7.8)
and then lyophilised and stored at -20°C until needed.
Approximately 4 mg of lyophilised protein was made up
in 500 µL of D2O for analysis. 19F NMR (564.5 MHz) data
were collected using a Bruker Avance 600 MHz spectrom-
eter fitted with a 5 mm dual 19F/1H probehead tuned to
19F. Standard parameters were11 261 Hz sweep width,
1.45 second acquisition time and a 0.5 second relaxation
delay. A 1 Hz line broadening was applied. Spectra were
recorded at 277 K and referenced to an external sample of
trifluoroacetic acid (set at-76.53 ppm) or a solution of
0.05 % trifluorotoluene in CDCl3 (set at -63 ppm) as
external references. Gd(EDTA)- line broadening experi-
ments were realized by adding 13 µL and later 26 µL of a
stock solution of Gd(EDTA)- (80 mM GdCl3, 500 mM
EDTA, pH 7.1 with NaOH) to the sample.
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